Artiva Biotherapeutics Approves Equity Plan Amendment at 2026 Annual Meeting

What Happened

• Artiva Biotherapeutics, Inc. (ARTV) filed an 8-K reporting results of its September 8, 2026 annual meeting. Stockholders approved an amendment to the company’s 2024 Equity Incentive Plan increasing the plan reserve by 5,097,095 shares and adding pre-funded warrants to the formula for the annual automatic share reserve increase. The amendment had been board-approved July 15, 2026 and the amended plan is filed as Exhibit 10.1 to the 8-K.
• At the meeting (record date July 20, 2026; 48,885,777 shares outstanding), Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. were re-elected for three-year terms. Stockholders also ratified KPMG LLP as the company’s independent registered public accounting firm for fiscal 2026. The 8-K was signed by CEO Fred Aslan on September 11, 2026.

Key Details

• Equity plan increase: 5,097,095 shares added to the 2024 Equity Incentive Plan (Amended 2024 Plan).
• Vote totals (record date shares outstanding = 48,885,777):
  • Equity plan amendment: For 32,527,133; Against 6,816,989; Abstentions 22,759; Broker non-votes 4,640,922.
  • Director elections: Brian Daniels — For 33,591,967; Withheld 5,774,914; Broker non-votes 4,640,922. Laura Stoppel — For 33,862,513; Withheld 5,504,368; Broker non-votes 4,640,922.
  • Auditor ratification (KPMG): For 44,000,762; Against 4,325; Abstentions 2,716.
• The added shares represent roughly a 10.4% increase relative to shares outstanding as of the meeting record date.

Why It Matters

• The equity plan amendment increases the pool of shares available for employee, director and consultant awards, which can support hiring and retention but may dilute existing shareholders as awards are granted and exercised. The filing provides the exact added share amount and the mechanism change to include pre-funded warrants in future automatic increases.
• Re-election of the two Class II directors and ratification of KPMG maintain board and auditor continuity, reducing near-term governance uncertainty. The detailed vote counts show meaningful dissent on the equity amendment (over 6.8M votes against), information investors can use when assessing governance and potential future dilution.